What is the latest MOLBIO stock price?
The latest stored price for MOLBIO is Rs n/a as of 2026-08-19.
gimli
MOLBIO stock AI analysis
MOLBIO Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
MOLBIO DIAGNOSTICS LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available MOLBIO price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹n/a
1W return
n/a
1M return
n/a
3M return
n/a
6M return
n/a
1Y return
n/a
Market cap
₹n/a
PE
n/a
PB
n/a
ROE
n/a
ROCE
n/a
RSI
n/a
Turnover
₹n/a
Why it can matter in screens
- Momentum: MOLBIO is 50DMA unavailable, 200DMA unavailable; RSI is n/a.
- Returns: 1D n/a, 1W n/a, 1M n/a, 3M n/a, 1Y n/a.
- Trend levels: 52W high ₹n/a, 52W low ₹n/a, off high n/a.
- Liquidity: latest turnover is ₹n/a; volume vs 20D is n/a.
- Valuation/profitability: PE n/a, PB n/a, ROE n/a, ROCE n/a.
- Growth: 3Y sales CAGR n/a, 3Y profit CAGR n/a.
Quick Answers
Is MOLBIO above its 50DMA and 200DMA?
MOLBIO is 50DMA unavailable, 200DMA unavailable. The latest 50DMA is n/a and the latest 200DMA is n/a.
What are MOLBIO PE, ROE and ROCE?
MOLBIO has PE n/a, ROE n/a, and ROCE n/a in Gimli's latest available snapshot.
How has MOLBIO performed recently?
MOLBIO has returned n/a over 1 month, n/a over 3 months, and n/a over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
No recent data available.
Annual income statement
No recent data available.
Balance sheet
No recent data available.
Cash flow
No recent data available.
Shareholding Trend
No recent data available.
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 455,873.65 cr | 37.630010 | +15.50% | +16.81% |
| DIVISLAB | DIVI S LABORATORIES LTD | 227,241.12 cr | 77.982540 | +18.37% | +40.80% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 169,662.68 cr | 77.791233 | +17.33% | +37.28% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 125,811.61 cr | 64.242041 | +21.03% | +11.84% |
| CIPLA | CIPLA LTD | 114,869.23 cr | 34.060659 | +10.25% | -8.19% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 111,138.55 cr | 22.163877 | +17.93% | +11.63% |
| LUPIN | LUPIN LIMITED | 101,730.54 cr | 14.882699 | +34.34% | +13.02% |
| MANKIND | MANKIND PHARMA LIMITED | 98,831.10 cr | 48.178798 | +13.18% | -3.94% |
Try these prompts
- Analyze MOLBIO DIAGNOSTICS with valuation, momentum and industry peers
- Compare MOLBIO with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare MOLBIO with other Healthcare stocks
Data snapshot: 2026-08-19. Not investment advice.